Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis
出版年份 2016 全文链接
标题
Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis
作者
关键词
Meta-analysis, Survival analysis, Oncology, Statistical models, Multivariate analysis, Phase III clinical investigation, Randomized controlled trials, Statistical methods
出版物
PLoS One
Volume 11, Issue 5, Pages e0154870
出版商
Public Library of Science (PLoS)
发表日期
2016-05-06
DOI
10.1371/journal.pone.0154870
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
- (2015) Ryo Kitagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation
- (2015) Beryl McCormick et al. JOURNAL OF CLINICAL ONCOLOGY
- Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910
- (2015) Thomas M. Pisansky et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
- (2015) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial
- (2015) Marie A. Bakitas et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
- (2015) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- (2015) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
- (2015) Laurence Klotz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
- (2015) Miguel Martín et al. JOURNAL OF CLINICAL ONCOLOGY
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
- (2015) George T. Budd et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
- (2015) Uwe Pelzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
- (2015) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2015) Xavier Pivot et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia
- (2015) Richard M. Stone et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
- (2015) Malcolm D. Mason et al. JOURNAL OF CLINICAL ONCOLOGY
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2015) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
- (2015) Tetsuya Abe et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
- (2015) Karen A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- Timing of Adjuvant Surgical Oophorectomy in the Menstrual Cycle and Disease-Free and Overall Survival in Premenopausal Women With Operable Breast Cancer
- (2015) Richard R. Love et al. JNCI-Journal of the National Cancer Institute
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
- (2015) Jean-Yves Blay et al. LANCET ONCOLOGY
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
- (2015) Daniel P Petrylak et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Timing of Adjuvant Surgical Oophorectomy in the Menstrual Cycle and Disease-Free and Overall Survival in Premenopausal Women With Operable Breast Cancer
- (2015) Richard R. Love et al. JNCI-Journal of the National Cancer Institute
- Reporting quality of survival analyses in medical journals still needs improvement. A minimal requirements proposal
- (2013) Víctor Abraira et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
- (2013) Shannon Cope et al. VALUE IN HEALTH
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Network meta-analysis of survival data with fractional polynomials
- (2011) Jeroen P Jansen BMC Medical Research Methodology
- Network meta-analysis of parametric survival curves
- (2011) Mario J. N. M. Ouwens et al. Research Synthesis Methods
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals
- (2008) Simone Mathoulin-Pelissier et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-analysis of summary survival curve data
- (2008) Lidia R. Arends et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now